M D Anderson Cancer Center — Houston, Texas

Public research footprint of M D Anderson Cancer Center, compiled from the ClinicalTrials.gov public registry.

1,790

Registered studies

802

Active

342

Recruiting now

677

Completed

267

Stopped or withdrawn

Most-studied conditions

Leukemia · Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma · Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma · Recurrent Acute Myeloid Leukemia

Recently updated registry entries

NCT07377526 — TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer (Suspended)
NCT03011814 — Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory… (Recruiting)
NCT05703854 — Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction… (Suspended)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at M D Anderson Cancer Center?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.